Advocacy intelligence hub — real-time data for patient organizations
Campus Bio-Medico University — NA
1ST Biotherapeutics, Inc. — PHASE1
Relyvrio: FDA approved
Treatment of amyotrophic lateral sclerosis (ALS) in adults
Tiglutik: FDA approved
TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
EXSERVAN: FDA approved
EXSERVAN is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Radicava: FDA approved
Treatment of amyotrophic lateral sclerosis (ALS)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance3
Radicava
Tanabe Pharma America Inc.
Relyvrio
Amylyx Pharmaceuticals, Inc.
EXSERVAN
Aquestive Therapeutics
Tiglutik
(riluzole oral suspension)Orphan drugItalfarmaco SpA
Benzothiazole [EPC]
12.1 Mechanism of Action The mechanism by which riluzole exerts its therapeutic effects in patients with ALS is unknown.
EXSERVAN
(riluzole oral film)Orphan drugAquestive Therapeutics
Radicava
(edaravone)Orphan drugTanabe Pharma America Inc.
12.1 Mechanism of Action The mechanism by which RADICAVA and RADICAVA ORS exert their therapeutic effect in patients with ALS is unknown.
Qalsody
(tofersen)Orphan drugacceleratedBiogen Inc.
Antisense Oligonucleotide [EPC]
12.1. Mechanism of Action Tofersen is an antisense oligonucleotide that causes degradation of SOD1 mRNA through binding to SOD1 mRNA, which results in...
Jakub M Antczak, MD
Jagiellonian University Medical College, Department of Neurology
📍 Krakow, Lesser Poland Voivodeship
Christopher Mcdermott
Sheffield Institute for Translational Neuroscience
Paul Barkhaus, MD
Medical College of Wisconsin
📍 MILWAUKEE, WI
Tulio Bertorini, MD
University of Tennessee Health Science Center
📍 MEMPHIS, TN
Jesse Crayle, MD
Washington University
📍 SAINT LOUIS, MO
Clara Meijs
Helmholtz Munich